by Plus Therapeutics | Aug 19, 2025 | LM
The Leptomeningeal Cancer Foundation is hosting an important webinar on Thursday, August 21, 2025 at 11 AM PDT / 2 PM EDT, featuring two leading oncologists: Dr. Seema Nagpal – neuro-oncologist Dr. Mohana Roy – thoracic oncologist Date & Time: Thursday, August 21,...
by Plus Therapeutics | Aug 18, 2025 | LM
Plus Therapeutics (NASDAQ: PSTV) announced positive data from the ReSPECT-LM Phase 1 single dose escalation clinical trial, presented at the podium during the Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference....
by Plus Therapeutics | Aug 14, 2025 | LM
Plus Therapeutics (NASDAQ: PSTV) presented encouraging data from a retrospective analysis of the CNSide® Cerebrospinal Fluid (CSF) Assay Platform at the 2025 Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference in...
by Plus Therapeutics | Aug 12, 2025 | LM
Leptomeningeal Metastases (LM) is a devastating complication of advanced cancers, where cancer cells spread to the cerebrospinal fluid and leptomeninges of the brain and spinal cord. Research and collaboration are critical to improving outcomes for patients facing...
by Plus Therapeutics | Aug 7, 2025 | GBM
Glioblastoma (GBM) is one of the most aggressive and challenging forms of brain cancer, with limited treatment options available today. At Plus Therapeutics (NASDAQ: PSTV), we are committed to developing new therapies that can bring hope to patients and their...
Recent Comments